Omega-3 Benefits Remain Strong Post-STRENGTH

Eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, the 2 main omega-3 long-chain polyunsaturated fatty acids of marine origin, have shown promise for the prevention of cardiovascular disease (CVD) outcomes in animal studies and epidemiologic studies.1 Although several recent trials have shown benefits, as summarized in Mayo Clinic Proceedings in 2019,2 2 randomized control trials published in late 2020 showed neutral results. The situation is summarized thoughtfully in a recent editorial by Farukhi et  al, published in Mayo Clinic Proceedings,3 which cited our recent meta-analysis6 on the subject.
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Tags: Letter to the editor Source Type: research